LMRA Lumera Corpration (MM)

Lumera Corporation (NASDAQ:LMRA), an emerging leader in the field of nanotechnology, was pleased to direct its various constituencies today to the recent publication by Nature magazine of an article on the subject of the growing capacity and need for protein arrays. Lumera was one of the companies interviewed for the article which was published in the December 14 issue of Nature magazine. The well-known science magazine interviewed Dr. Tim Londergan, director of the Lumera�s Bioscience Business Unit, and Ron Dudek, product group manager, who discussed the field and Lumera�s ability to offer higher protein array throughputs with its ProteomicProcessor� over other available instruments. A link to a PDF file of the article can be found at http://www.nature.com/nature/journal/v444/n7121/index.html. Nature is a weekly international journal publishing highly regarded peer-reviewed research in all fields of science and technology and provides authoritative, insightful news and coming trends affecting science, scientists and the wider public. Tom Mino, President and Chief Executive Officer of Lumera, said, �We see growing interest in the scientific and research communities concerning Lumera�s proprietary technology and we�re gratified to have a publication of Nature�s caliber take notice. We are scheduled to showcase the ProteomicProcessor� at a major protein conference in January and look forward to the response from potential customers.� About Lumera Lumera is a leader in the emerging field of nanotechnology. The company designs proprietary molecular structures and polymer compounds for the bioscience and communications/computing industries, both of which represent large market opportunities. The company also has developed proprietary processes for fabricating such devices. For more information, please visit www.lumera.com. Certain statements contained in this release are forward-looking statements that involve a number of risks and uncertainties. Factors that could cause actual results to differ materially from those projected in the company's forward-looking statements include the following: market acceptance of our technologies and products; our ability to obtain financing; our financial and technical resources relative to those of our competitors; our ability to keep up with rapid technological change; government regulation of our technologies; our ability to enforce our intellectual property rights and protect our proprietary technologies; the ability to obtain additional contract awards and to develop partnership opportunities; the timing of commercial product launches; the ability to achieve key technical milestones in key products; and other risk factors identified from time to time in the company's SEC reports, including its Annual Report on Form 10-K, and its Quarterly Reports on Form 10-Q.